DTC Ad Delay Pending Collection Of Post-Marketing Data Endorsed By ASHP

Direct-to-consumer advertising should be delayed for new drug products pending analysis of post-marketing surveillance data, the American Society of Health-System Pharmacists suggested at an FDA public hearing Nov. 1-2